The DaVita Healthcare Partners settlement of 2014 was a defining moment in the fight against illegal financial relationships in healthcare. It is a key case in demonstrating how whistleblowers can expose physician kickback schemes hidden behind legitimate-looking business deals. DaVita, one of the largest kidney care/dialysis providers in the U.S., agreed to pay $389 million […]
DaVita Healthcare Settlement (2014) Read More »
In 2012, Abbott Laboratories agreed to pay $1.5 billion to resolve criminal and civil allegations related to the unlawful promotion of its anti-seizure drug, Depakote. For Barrett Johnston, this case stands as a powerful example of how whistleblowers can hold even the largest pharmaceutical companies accountable for deceptive practices. Abbott was accused of marketing Depakote
Abbott Laboratories $1.5 Billion Settlement (2012) Read More »
The Tenet Healthcare fraud case of 2006 revealed just how deeply kickback schemes and improper financial incentives can distort patient care in the U.S. healthcare system. At Barrett Johnston, we point to this case as a key example of how whistleblowers expose corruption that harms both patients and taxpayers. In 2006, Tenet Healthcare Corporation, one
Tenet Healthcare Fraud Case (2006) Read More »
The Johnson & Johnson (J&J) $2.2 billion settlement in 2013 stands as another major milestone in healthcare fraud enforcement—particularly in curbing deceptive pharmaceutical marketing. The case centered on allegations that J&J and its subsidiaries promoted several prescription drugs, including Risperdal and Invega, for off-label uses not approved by the FDA. The company was also accused
Johnson & Johnson $2.2 Billion Settlement (2013) Read More »
Few cases better illustrate the scale of healthcare fraud than the qui tam action against HCA Healthcare. That case ultimately settled in 2000 and marked a major achievement in federal FCA enforcement. The case stemmed from widespread allegations that HCA, one of the largest hospital chains in the U.S., engaged in fraudulent billing practices. The
HCA Healthcare Fraud Settlement (2000) Read More »
The Pfizer $2.3 billion settlement in 2009 was a watershed moment in healthcare fraud enforcement. Not only was it the largest healthcare fraud settlement in U.S. history at the time, but it also showcased the power of whistleblowers in holding the world’s biggest pharmaceutical companies accountable. The case revolved around allegations of Pfizer illegally promoting
Pfizer $2.3 Billion Settlement (2009) Read More »
Qui tam cases filed by whistleblowers don’t just result in financial recoveries — someitmes they reshape entire industries. United States ex rel. Franklin v. Parke-Davis (2004) is an example of such industry-shifting cases. The whistleblower in that case was Dr. David Franklin, a former medical liaison at Parke-Davis, a subsidiary of Warner-Lambert (later acquired by
United States ex rel. Franklin v. Parke-Davis (2004) Read More »
In 2012, GlaxoSmithKline (GSK) agreed to pay $3 billion in what was then the largest healthcare fraud settlement in U.S. history. At Barrett Johnston, we highlight this case because it shows the incredible scale of misconduct that whistleblowers and federal investigators can uncover when they work together. The case centered on allegations that GSK engaged
GlaxoSmithKline $3 Billion Settlement (2012) Read More »
